- Home
- BRT vs DCTH Comparison
BRT vs DCTH Comparison
Compare BRT & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRT | DCTH |
|---|---|---|
| Founded | 1972 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 285.9M | 323.1M |
| IPO Year | 1994 | 2015 |
Fundamental Metrics
Financial Performance| Metric | BRT | DCTH |
|---|---|---|
| Price | $14.66 | $9.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $19.75 | ★ $23.00 |
| AVG Volume (30 Days) | 27.8K | ★ 457.1K |
| Earning Date | 01-01-0001 | 04-11-2026 |
| Dividend Yield | ★ 6.83% | N/A |
| EPS Growth | N/A | ★ 68.37 |
| EPS | N/A | ★ 0.12 |
| Revenue | ★ $95,630,000.00 | N/A |
| Revenue This Year | N/A | $132.21 |
| Revenue Next Year | $3.72 | $35.72 |
| P/E Ratio | ★ N/A | $81.50 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.00 | $8.12 |
| 52 Week High | $19.01 | $18.23 |
Technical Indicators
Market Signals| Indicator | BRT | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 48.78 | 46.05 |
| Support Level | $14.55 | $9.31 |
| Resistance Level | $15.09 | $9.65 |
| Average True Range (ATR) | 0.32 | 0.48 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 40.21 | 45.71 |
Price Performance
Historical ComparisonAbout BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.